Results 41 to 50 of about 8,597,475 (170)

Aflibercept 8 mg in Neovascular AMD—A Fast-Drying Anti-VEGF Drug: A Prospective Morpho-Functional Pilot Study [PDF]

Ophthalmology and Therapy
Introduction This study investigated early anatomical and functional outcomes in patients with treatment-naïve neovascular age-related macular degeneration (nAMD) treated with 8 mg aflibercept compared to patients treated with the standard dose of 2 mg ...
Michele Rinaldi, Gilda Cennamo, Marina Concilio, Gaetano Corvino, Alessia Riccardo, Raffaele Nubi, Ciro Costagliola   +6 more
doaj   +2 more sources

One-Year Real-World Outcomes of Intravitreal Aflibercept 8 mg for Neovascular Age-Related Macular Degeneration in Japan: A Multicenter Retrospective Study [PDF]

Clinical Ophthalmology
Rikuto Mizuma,1,* Yuki Mizuki,1– 3,* Akihiro Kamata,4 Junji Onishi,4 Takuto Sakono,1 Misa Suzuki,1,5 Nobuhisa Mizuki1 1Department of Ophthalmology and Visual Science, Yokohama City University Graduate School of Medicine, Yokohama, Japan ...
Mizuma R, Mizuki Y, Kamata A, Onishi J, Sakono T, Suzuki M, Mizuki N   +6 more
doaj   +2 more sources

The clinical utility of aflibercept for diabetic macular edema

Diabetes, Metabolic Syndrome and Obesity, 2015
Michael W StewartDepartment of Ophthalmology, Mayo School of Medicine, Jacksonville, FL, USAAbstract: The treatment of center-involving diabetic macular edema (DME) has improved because of the proven efficacy of drugs that inhibit the effects of vascular
Stewart MW
doaj   +1 more source

Inflammation and increased intraocular pressure associated with intravitreal aflibercept 8 mg: A systematic review and meta-analysis

AJO International
Topic: Aflibercept 8 mg was recently approved for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME).
Nikoline Skindhøj Rebsdorf, Marie Martine Michaelsen, Natasja Kærmose Ølholm, Suffía Olsen, Celine Lee, Yousif Subhi, Marie Ørskov, Henrik Vorum, Lasse Jørgensen Cehofski   +8 more
doaj   +2 more sources

Summary of Research: Aflibercept 8 mg versus Faricimab Treat‑and‑Extend for Diabetic Macular Edema or Neovascular Age‑Related Macular Degeneration: A Bayesian Fixed‑Effect Network Meta‑analysis of Clinical Trials [PDF]

Ophthalmology and Therapy
This is a summary of the original research article “Aflibercept 8 mg versus Faricimab Treat‑and‑Extend for Diabetic Macular Edema or Neovascular Age‑Related Macular Degeneration: A Bayesian Fixed‑Effect Network Meta‑analysis of Clinical Trials.” Diabetic
Scott M. Friedman, Yingxin Xu, Steven Sherman, Andreas Kuznik, Ali Mojebi, Sam Keeping, Keith Chan, Theodore Leng, Nimesh A. Patel   +8 more
doaj   +2 more sources

Author Correction: Sustainability in medical retina: the environmental impact of using aflibercept 8 mg instead of aflibercept 2 mg in treatment-naïve patients with nAMD. [PDF]

Eye (Lond)
Bowley N, Thomas P, Sivaprasad S, Purbrick RMJ, Beardmore E, Gilbert R, Clarke A, Chase TJG.   +7 more
europepmc   +2 more sources

Pharmacokinetic and Pharmacodynamic Rationale for Extending VEGF Inhibition Increasing Intravitreal Aflibercept Dose

Pharmaceutics, 2023
Background: The effects of various dosages and treatment regimens on intravitreal aflibercept concentrations and the proportion of free vascular endothelial growth factor (VEGF) to total VEGF were evaluated using a drug and disease assessment model.
Daniele Veritti, Valentina Sarao, Francesco Di Bin, Paolo Lanzetta   +3 more
doaj   +1 more source

Aflibercept 8 mg treat-and-extend pathway for the treatment of neovascular age-related macular degeneration: guidance from a UK expert panel. [PDF]

Eye (Lond)
Therapies with robust visual outcomes and reduced patient and healthcare system treatment burden are needed amidst the rising incidence of neovascular age-related macular degeneration (nAMD).
Gale R, Awad MH, Bailey C, Cackett P, Chhabra R, Downey L, Ghanchi F, Kotagiri A, Narendran N, Pearce I, Peto T, Sivaprasad S, Younis S, Napier J, Gilbert R, Ismat S.   +15 more
europepmc   +2 more sources

The Efficacy and Safety of Intravitreal Aflibercept 8 mg in Clinical Practice

Journal of VitreoRetinal Diseases
Purpose: To characterize real-world use of intravitreal aflibercept 8 mg across 22 US retina practices. Methods: A retrospective review was performed of patients who received at least 1 intravitreal aflibercept 8 mg injection for treatment of neovascular age-related ...
Brandon A. Bates, Hana A. Mansour, Hasenin Al-khersan, Edward Wood, Bita Momenaei, Eric Schneider, Collin J. Richards, Charles DeYoung, Charles C. Wykoff, Kevin Quinn, Jason Hsu, Carl D. Regillo, Allen C. Ho, Mitchell S. Fineman, Michael A. Klufas, Philip P. Storey   +15 more
openaire   +2 more sources

Potential of Nanoparticle‐Based Phototherapies for Future Treatment of Uveal Melanoma

Advanced Science, EarlyView.
This review evaluates nanoparticle‐based phototherapies for uveal melanoma, highlighting emerging strategies to enhance tumor targeting, light delivery, and treatment precision. Preclinical data indicate improved efficacy and reduced toxicity, supporting their potential to enhance localized treatment and future translational advances. (Generated by the
Emilie Lambert, Christophe Nguyen, Sean Edward Dunn, Magali Gary‐Bobo, Jérôme Lacombe, Justin Moser, Frédéric Zenhausern, Jean‐Olivier Durand, Frédérique Cunin   +8 more
wiley   +1 more source